Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg
Clinical trial NCT03350295 · COMPLETED
Trial details
- NCT number
- NCT03350295
- Sponsor
- Bayer
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-14
- Primary completion
- 2018-09-18
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.